X-Linked Hypophosphatemia Market Research Report - Global Forecast till 2027

Global X-Linked Hypophosphatemia Market: By Treatment (Medication, Surgical, or Orthopedic Treatment), End User (Hospitals and Clinics, Research Centers) & Region (Americas, Europe, Asia-Pacific & RoW) - Forecast till 2027

ID: MRFR/LS/4806-CR | August 2019 | Region: Global | 73 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data.

The Global X-Linked Hypophosphatemia Market is expected to register a CAGR of 3.6% to reach USD 40,309.1 Thousand by 2025.


X-linked hypophosphatemia (XLH) is an inherited disorder characterized by low levels of phosphate in the blood. The phosphate levels reduce as it is abnormally processed in the kidneys, which leads to the loss of phosphate through urine (phosphate wasting) and leads to soft and weak bones, causing rickets. XLH is usually diagnosed in childhood, and symptoms include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is caused by mutations in the PHEX gene on the X chromosome, and the inheritance of the X-linked is dominant. The treatment generally involves supplements of phosphate and high-dose calcitriol (an active form of vitamin D) and may also include growth hormones and corrective surgery. The key factors responsible for driving the market are the increasing prevalence rates of XLH, growing awareness about XLH. However, negative psychological and emotional impacts of having X-linked hypophosphatemia, post-operative complications, unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures are hindering the growth of the global X-linked hypophosphatemia market.


Market Dynamics


XLH is an inherited phosphate metabolism disorder in which inactivating mutations of the PHEX gene lead to local and systemic effects such as impaired growth, rickets, hearing difficulties, enthesopathy, osteomalacia, bone pain, bone abnormalities, spontaneous dental abscesses, osteoarthritis, and muscular dysfunction. Due to the rising cases of XLH in developing and developed economies, the global XLH market is expected to grow at a steady rate during the forecast period. For instance, according to the European Journal of Endocrinology statistics published in 2016, the incidence of XLH has been estimated to be 3.9 per 100,000 live births and has a prevalence of 4.8 per 100,000 people. Also, according to the study published in May 2016 by NIHR Horizon Scanning Research & Intelligence Centre, XLH affected more than 500 children in the UK.


Similarly, according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. And according to a report published in 2017 by the National Institute for Health and Care Excellence, there were approximately 250 children and young people with XLH in England, and up to 2,500 adults, till date. Thus, the overall market growth is projected to rise owing to the rising prevalence rates of XLH, which required adequate drugs and therapies for treatment.


Global X-Linked Hypophosphatemia Market Revenue, by Treatment, 2018 (USD Thousands)  X-linked Hypophosphatemia Market


Sources: MRFR Analysis


Segmentation


The X-linked hypophosphatemia (XLH) market by treatment has been segmented into medication and Surgical or orthopedic treatment. The X-linked hypophosphatemia market has been categorized by the end user into hospitals and clinics and research centers. The research centers segment is expected to account for the largest market share during the forecast period attributing to the increasing prevalence of XLH, increasing awareness regarding the disease, and growing research activity for its treatment.


The global X-linked hypophosphatemia market, by region, is segmented into the Americas, Europe, Asia-Pacific, and RoW. Factors such as the increasing prevalence of XLH and increasing awareness about the disorder are anticipated to propel the growth of the global X-Linked hypophosphatemia market.


Global X-linked Hypophosphatemia Market Share, by Region, 2018 (%)      X-linked Hypophosphatemia Market           


Sources: MRFR Analysis


Regional Analysis


The XLH market in the Americas is expected to hold a major market share owing to the growing prevalence of XLH in the US and Canada and the presence of a well-established healthcare sector. The rising research funding towards rare diseases such as XLH and the high healthcare expenditure is also expected to fuel the growth of the market during the forecast period. For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology. Similarly, the International Rare Diseases Research Consortium (IRDiRC) is a Scientific Secretariat that works in collaboration with Orphanet. Since 2010, IRDiRC financed over 3,000 projects. Moreover, according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. Moreover, the rising government funding for the healthcare sector, the increasing prevalence rate of rare diseases, and research funding are expected to propel the growth of the market in this region.


Key Players


The prominent players in the global X-linked hypophosphatemia (XLH) market are Ultragenyx Pharmaceutical, Validus Pharmaceuticals LLC, Prospec-Tany Technogene Ltd, Merck KGaA, Zeria Pharmaceutical Co., Ltd, Smith & Nephew, Narang Medical Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Others.


The players operating in the global X-linked hypophosphatemia (XLH) market are focusing on product launches, along with expanding their global footprints by entering untapped markets.


Market Segmentation


Global X-Linked Hypophosphatemia Market, by Treatment



  • Medication

  • Surgical or Orthopedic Treatment


Global X-Linked Hypophosphatemia Market, by End User



  • Hospitals and Clinics

  • Research Centers


Global X-Linked Hypophosphatemia Market, by Region



  • Americas

    • North America

      • US

      • Canada

      • South America







  • Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe





  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia & New Zealand

    • Southeast Asia

    • Rest of Asia-Pacific





  • Rest of the World

    • Middle East

    • Africa




Available Additional Customizations


Company Profiles of Key Regional Players



  • Kyowa Hakko Kirin

  •  Smith & Nephew

  • Nestle

  • Pfizer

  • Koninklijke DSM

  • ADM Alliance Nutrition


Intended Audience



  • Drug Suppliers

  • Research and Development (R&D) Companies

  • Government Research Laboratories

  • Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 40,309.1 Thousand
  CAGR   3.6% (2019-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Thousands)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Ultragenyx Pharmaceutical, Validus Pharmaceuticals LLC, Prospec-Tany Technogene Ltd, Merck KGaA, Zeria Pharmaceutical Co., Ltd, Smith & Nephew, Narang Medical Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd
  Key Market Opportunities   A recent drug approval by regulatory authorities are likely to offer lucrative opportunities for the growth of the market
  Key Market Drivers

  • Rising cases of X-linked hypophosphatemia.
  • Increasing awareness about XLH and the severity of the disease


  • Frequently Asked Questions (FAQ) :


    X-Linked Hypophosphatemia Market CAGR would be 3.6% during the forecast period.

    X-Linked Hypophosphatemia Market valuation would be USD 40309.1 thousand by 2025.

    The research centers segment would X-Linked Hypophosphatemia Market.

    The Americas would dominate X-Linked Hypophosphatemia Market

    Players involved in X-Linked Hypophosphatemia Market are Validus Pharmaceuticals LLC, Ultragenyx Pharmaceutical, Merck KGaA, Prospec-Tany Technogene Ltd, Narang Medical Limited, Zeria Pharmaceutical Co., Ltd, Smith & Nephew, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, and Others.

    1 Executive Summary

    2 Market Introduction

    2.1 Scope of the Study 13

    2.2 Research Objective 13

    2.3 List of Assumptions 14

    3 Research Methodology

    3.1 Research Methodology - X-Linked Hypophosphatemia Market 15

    3.2 Data Mining 16

    3.3 Secondary Research 16

    3.3.1 Data points received from the secondary research 17

    3.4 Primary Research 17

    3.4.1 Data points received from surgeons, & consulting physicians 18

    3.4.2 Data points received from the manufacturer 19

    3.5 Forecasting Techniques 19

    3.6 Research Methodology for Market Size Estimation X-Linked Hypophosphatemia Market: 20

    3.6.1 Assumptions 21

    3.7 Data Triangulation 22

    3.8 Validation 22

    4 Market Dynamics

    4.1 Overview 23

    4.2 Drivers 24

    4.2.1 Increasing Prevalence Rate of XLH 24

    4.2.2 Growing Awareness about XLH 24

    4.2.3 Increasing Research 24

    4.2.4 Driver Impact Analysis 25

    4.3 Restraints 26

    4.3.1 Side-Effects Associated with Burosumab 26

    4.3.2 High Cost of Burosumab 26

    4.3.3 Limited Availability of Treatment Options 26

    4.3.4 Restraint Impact Analysis 27

    4.4 Opportunity 28

    4.4.1 Recent Regulatory Approvals 28

    5 Market Factor Analysis

    5.1 Value Chain Analysis 29

    5.1.1 Overview 29

    5.1.2 R&D 29

    5.1.3 Manufacturing 29

    5.1.4 Distribution and Sales 29

    5.1.5 Post-Sales Monitoring 30

    5.2 Porter’s Five Forces Model 31

    5.2.1 Overview 31

    5.2.2 Bargaining Power of Suppliers 32

    5.2.3 Bargaining Power of Buyers 32

    5.2.4 The threat of New Entrants 32

    5.2.5 Threat of Substitutes 32

    5.2.6 Intensity of Rivalry 32

    6 X-Linked Hypophosphatemia Market, by Treatment

    6.1 Introduction 33

    6.2 Medication 34

    6.3 Surgical or Orthopedic Treatment 34

    7 X-Linked Hypophosphatemia Market, by End User

    7.1 Introduction 35

    7.2 Hospitals and Clinics 36

    7.3 Research Centers 36

    8 Global X-Linked Hypophosphatemia Market, by Region

    8.1 Introduction 37

    8.2 Americas 39

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.2.1 North America 40

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.2.1.1 US 41

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.2.1.2 Canada 42

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.2.2 South America 42

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.3 Europe 43

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.3.1 Germany 44

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.3.2 France 45

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.3.3 UK 45

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.3.4 Italy 46

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.3.5 Spain 46

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.3.6 Rest of Europe 47

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.4 Asia-Pacific 48

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.4.1 China 49

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.4.2 Japan 50

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.4.3 India 50

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.4.4 South Korea 51

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.4.5 Australia 51

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.4.6 Rest of Asia-Pacific 52

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    8.5 RoW 53

    X-Linked Hypophosphatemia Market, by Treatment

    X-Linked Hypophosphatemia Market, by End User

    9 Competitive landscape

    9.1 Introduction 54

    9.2 Key developments 55

    10 Company Profiles

    10.1 Ultragenyx Pharmaceutical 57

    10.1.1 Company Overview 57

    10.1.2 Financial Overview 57

    10.1.3 Products/Services Offered 58

    10.1.4 Key Developments 58

    10.1.5 SWOT Analysis 58

    10.1.6 Key Strategies 59

    10.2 Validus Pharmaceuticals LLC 60

    10.2.1 Company Overview 60

    10.2.2 Financial Overview 60

    10.2.3 Products/Services Offered 60

    10.2.4 Key Developments 60

    10.2.5 SWOT Analysis 60

    10.2.6 Key Strategies 61

    10.3 Prospec-Tany Technogene Ltd 62

    10.3.1 Company Overview 62

    10.3.2 Financial Overview 62

    10.3.3 Products/Services Offered 62

    10.3.4 Key Developments 62

    10.3.5 SWOT Analysis 63

    10.3.6 Key Strategies 63

    10.4 Merck KGaA 64

    10.4.1 Company Overview 64

    10.4.2 Financial Overview 64

    10.4.3 Products/Services Offered 64

    10.4.4 Key Developments 65

    10.4.5 SWOT Analysis 65

    10.4.6 Key Strategies 65

    10.5 Zeria Pharmaceutical Co., Ltd 66

    10.5.1 Company Overview 66

    10.5.2 Financial Overview 66

    10.5.3 Products/Services Offered 66

    10.5.4 Key Developments 66

    10.5.5 SWOT Analysis 67

    10.5.6 Key Strategies 67

    10.6 Smith & Nephew 68

    10.6.1 Company Overview 68

    10.6.2 Financial Overview 68

    10.6.3 Products/Services Offered 68

    10.6.4 Key Developments 69

    10.6.5 SWOT Analysis 69

    10.6.6 Key Strategies 69

    10.7 Narang Medical Limited 70

    10.7.1 Company Overview 70

    10.7.2 Financial Overview 70

    10.7.3 Products/Services Offered 70

    10.7.4 Key Developments 70

    10.7.5 SWOT Analysis 71

    10.7.6 Key Strategies 71

    10.8 Eli Lilly and Company 72

    10.8.1 Company Overview 72

    10.8.2 Financial Overview 72

    10.8.3 Products/Services Offered 72

    10.8.4 Key Developments 73

    10.8.5 SWOT Analysis 73

    10.8.6 Key Strategies 73

    10.9 F. Hoffmann-La Roche Ltd 74

    10.9.1 Company Overview 74

    10.9.2 Financial Overview 74

    10.9.3 Products/Services Offered 74

    10.9.4 Key Developments 75

    10.9.5 SWOT Analysis 75

    10.9.6 Key Strategies 75

    10.10 Illumina, Inc. 76

    10.10.1 Company Overview 76

    10.10.2 Financial Overview 76

    10.10.3 Products/Services Offered 77

    10.10.4 Key Developments 77

    10.10.5 SWOT Analysis 78

    10.10.6 Key Strategies 78

    10.11 Biomedica Medizinprodukte GmbH 79

    10.11.1 Company Overview 79

    10.11.2 Financial Overview 79

    10.11.3 Products/Services Offered 79

    10.11.4 Key Developments 79

    10.11.5 SWOT Analysis 79

    10.11.6 Key Strategies 80

    10.12 QIAGEN 81

    10.12.1 Company Overview 81

    10.12.2 Financial Overview 81

    10.12.3 Products/Services Offered 82

    10.12.4 Key Developments 82

    10.12.5 SWOT Analysis 82

    10.12.6 Key Strategies 82

    11 Appendix

    11.1 References 83

    11.2 Related Reports 83


    12 List of Tables

    TABLE 1 LIST OF ASSUMPTIONS 14

    TABLE 2 PORTER’S FIVE FORCES ANALYSIS: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET 31

    TABLE 3 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 33

    TABLE 4 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR MEDICATION, BY REGION 2020–2027 (USD THOUSANDS) 34

    TABLE 5 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR SURGICAL OR ORTHOPEDIC TREATMENT, BY REGION 2020–2027

    (USD THOUSANDS) 34

    TABLE 6 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 35

    TABLE 7 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR HOSPITALS AND CLINICS, BY REGION 2020–2027 (USD THOUSANDS) 36

    TABLE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR RESEARCH CENTERS, BY REGION 2020–2027 (USD THOUSANDS) 36

    TABLE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 2020–2027 (USD THOUSANDS) 38

    TABLE 10 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 2020–2027 (USD THOUSANDS) 39

    TABLE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 39

    TABLE 12 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 40

    TABLE 13 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY 2020–2027 (USD THOUSANDS) 40

    TABLE 14 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 41

    TABLE 15 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 41

    TABLE 16 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 41

    TABLE 17 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 41

    TABLE 18 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 42

    TABLE 19 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 42

    TABLE 20 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 42

    TABLE 21 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 42

    TABLE 22 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 2020–2027 (USD THOUSANDS) 43

    TABLE 23 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 44

    TABLE 24 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 44

    TABLE 25 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 44

    TABLE 26 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 44

    TABLE 27 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 45

    TABLE 28 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 45

    TABLE 29 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 45

    TABLE 30 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 45

    TABLE 31 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 46

    TABLE 32 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 46

    TABLE 33 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 46

    TABLE 34 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 46

    TABLE 35 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 47

    TABLE 36 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 47

    TABLE 37 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 2020–2027 (USD THOUSANDS) 48

    TABLE 38 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 49

    TABLE 39 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 49

    TABLE 40 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 49

    TABLE 41 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 49

    TABLE 42 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 50

    TABLE 43 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 50

    TABLE 44 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 50

    TABLE 45 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 50

    TABLE 46 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 51

    TABLE 47 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 51

    TABLE 48 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 51

    TABLE 49 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 51

    TABLE 50 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 52

    TABLE 51 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 52

    TABLE 52 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 53

    TABLE 53 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 53

    TABLE 54 KEY DEVELOPMENTS, BY PLAYERS IN THE MARKET 55


    13 List of Figures

    FIGURE 1 MARKET SYNOPSIS 12

    FIGURE 2 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET: STRUCTURE 14

    FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 21

    FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GROWTH HORMONE MARKET 23

    FIGURE 5 DRIVER IMPACT ANALYSIS 25

    FIGURE 6 RESTRAINT IMPACT ANALYSIS 27

    FIGURE 7 SUPPLY CHAIN: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET 29

    FIGURE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020 & 2027 (USD THOUSANDS) 33

    FIGURE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020 & 2027 (USD THOUSANDS) 36

    FIGURE 10 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2020 (%) 38

    FIGURE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2020 (%) 39

    FIGURE 12 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY 2020 (%) 40

    FIGURE 13 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2020 (%) 43

    FIGURE 14 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2020 (%) 48

    FIGURE 15 MAJOR PLAYERSCATEGORY-WISE SHARE OF KEY DEVELOPMENTS 56